{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:16:06Z","timestamp":1770297366296,"version":"3.49.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/mcg.0b013e31827e46be","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T15:41:29Z","timestamp":1361893289000},"page":"672-677","source":"Crossref","is-referenced-by-count":17,"title":["Obesity Does Not Affect Treatment Outcomes With Proton Pump Inhibitors"],"prefix":"10.1097","volume":"47","author":[{"given":"Prateek","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimish","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Monyak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra G.","family":"Silberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2009.2014","article-title":".Prevalence and trends in obesity among US adults, 1999-2008.","volume":"303","author":"Flegal","year":"2010","journal-title":"JAMA"},{"key":"R3-5-20210305","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/gut.2004.051821","article-title":".Epidemiology of gastro-oesophageal reflux disease: a systematic review.","volume":"54","author":"Dent","year":"2005","journal-title":"Gut"},{"key":"R4-5-20210305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-143-3-200508020-00006","article-title":"Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications.","volume":"143","author":"Hampel","year":"2005","journal-title":"Ann Intern Med"},{"key":"R5-5-20210305","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1440-1746.2006.04549.x","article-title":".Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study.","volume":"22","author":"Nocon","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R6-5-20210305","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMoa054391","article-title":".Body-mass index and symptoms of gastroesophageal reflux in women.","volume":"354","author":"Jacobson","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-5-20210305","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ije\/dyg108","article-title":".Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project.","volume":"32","author":"Murray","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R8-5-20210305","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0002-9343(99)00121-7","article-title":".Risk factors associated with symptoms of gastroesophageal reflux.","volume":"106","author":"Locke","year":"1999","journal-title":"Am J Med"},{"key":"R9-5-20210305","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1572-0241.2005.41703.x","article-title":".Obesity is an independent risk factor for GERD symptoms and erosive esophagitis.","volume":"100","author":"El-Serag","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R10-5-20210305","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.290.1.66","article-title":".Obesity and estrogen as risk factors for gastroesophageal reflux symptoms.","volume":"290","author":"Nilsson","year":"2003","journal-title":"JAMA"},{"key":"R11-5-20210305","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2006.100263","article-title":".Obesity increases oesophageal acid exposure.","volume":"56","author":"El-Serag","year":"2007","journal-title":"Gut"},{"key":"R12-5-20210305","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s11605-009-0930-7","article-title":".Obesity and gastroesophageal reflux: quantifying the association between body mass index, esophageal acid exposure, and lower esophageal sphincter status in a large series of patients with reflux symptoms.","volume":"13","author":"Ayazi","year":"2009","journal-title":"J Gastrointest Surg"},{"key":"R13-5-20210305","first-page":"553","article-title":".Obesity is associated with increased 48-hours esophageal acid exposure in patients with symptomatic gastroesophageal reflux.","volume":"104","author":"Crowell","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R14-5-20210305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","article-title":"Pharmacokinetic considerations in obesity.","volume":"88","author":"Blouin","year":"1999","journal-title":"J Pharm Sci"},{"key":"R15-5-20210305","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s10620-008-0414-8","article-title":"Body mass index and the efficacy of acid-mediating agents for GERD.","volume":"53","author":"Jacobson","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R16-5-20210305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1467-789X.2002.00049.x","article-title":".Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations.","volume":"3","author":"Barak","year":"2002","journal-title":"Obes Rev"},{"key":"R19-5-20210305","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2036.2003.01771.x","article-title":"Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis.","volume":"18","author":"Katz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-5-20210305","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":".Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R21-5-20210305","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":".Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R22-5-20210305","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","article-title":".Efficacy of esomeprazole 40 mg versus lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.","volume":"21","author":"Fennerty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-5-20210305","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":".Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial.","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-5-20210305","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10620-005-9062-4","article-title":".A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.","volume":"51","author":"Schmitt","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R25-5-20210305","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2036.2006.02983.x","article-title":".Predictors of treatment response in patients with non-erosive reflux disease.","volume":"24","author":"Talley","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R26-5-20210305","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.14309\/00000434-200709002-00089","article-title":".PPI efficacy in overweightobese patients with erosive GERD: rabeprazole (RAB) 20 mg versus omeprazole (OME) 20 mg abstract 89.","volume":"102","author":"Jacobson","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R27-5-20210305","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/j.1572-0241.2008.01979.x","article-title":".Body mass index can determine the healing of reflux esophagitis with Los Angeles grades C and D by esomeprazole.","volume":"103","author":"Sheu","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R28-5-20210305","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/003655202760230847","article-title":"Risk factors for the severity of erosive esophagitis in Helicobacter pylori-negative patients with gastroesophageal reflux disease.","volume":"8","author":"El-Serag","year":"2002","journal-title":"Scand J Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0b013e31827e46be","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:10:46Z","timestamp":1620961846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201309000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31827e46be","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}